XML 35 R25.htm IDEA: XBRL DOCUMENT v3.8.0.1
COMMON STOCK AND STOCK-BASED COMPENSATION PLANS (Tables)
9 Months Ended
Sep. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Summary of Stock Option Activity

A summary of the Company’s stock option and SARs activities and related information for the nine months ended September 30, 2017, are as follows:

 

     Number of
options and

SAR units (1)
     Weighted
average
exercise
price
     Weighted
average
remaining
contractual
term
    
Aggregate
intrinsic-value
 

Outstanding as of December 31, 2016

     1,455,908      $ 19.76        

Granted

     —          —          

Exercised

     (588,972      19.74        

Forfeited or expired

     (14,349      17.56        
  

 

 

    

 

 

       

Outstanding as of September 30, 2017 (2)

     852,587      $ 19.81        5.2      $ 19,598  
  

 

 

    

 

 

    

 

 

    

 

 

 

Exercisable as of September 30, 2017 (3)

     604,327      $ 19.18        4.7      $ 14,271  
  

 

 

    

 

 

    

 

 

    

 

 

 

 

(1) The SAR units are convertible for a maximum number of shares of the Company’s common stock equal to 75% of the SAR units subject to the grant.
(2) Due to the ceiling imposed on the SAR grants, the outstanding amount equals a maximum of 775,403 shares of the Company’s common stock issuable upon exercise.
(3) Due to the ceiling imposed on the SAR grants, the exercisable amount equals a maximum of 551,645 shares of the Company’s common stock issuable upon exercise.
Summary of Restricted Stock Units Activity

A summary of the Company’s RSU activities and related information for the nine months ended September 30, 2017, are as follows:

 

     Number of
RSUs
     Weighted Average
Grant-Date
Fair Value
 

Unvested as of December 31, 2016

     505,142      $ 21.59  

Granted

     269,497        36.84  

Vested

     (193,399      21.46  

Forfeited or expired

     (26,374      26.01  
  

 

 

    

 

 

 

Unvested as of September 30, 2017

     554,866      $ 28.84  
  

 

 

    

 

 

 
Equity-Based Compensation Expense Included in Interim Condensed Consolidated Statements of Income

The following table shows the total equity-based compensation expense included in the interim condensed consolidated statements of income:

 

     Nine months ended
September 30,
     Three months ended
September 30,
 
     2017      2016      2017      2016  
     (unaudited)      (unaudited)      (unaudited)      (unaudited)  

Cost of revenue

   $ 330      $ 179      $ 125      $ 65  

Research and development, net

     2,834        2,162        991        741  

Sales and marketing

     1,040        681        381        179  

General and administrative

     2,142        1,626        722        580  
  

 

 

    

 

 

    

 

 

    

 

 

 

Total equity-based compensation expense

   $ 6,346      $ 4,648      $ 2,219      $ 1,565  
  

 

 

    

 

 

    

 

 

    

 

 

 
Assumptions Used to Estimate Fair Value of Employee Stock Purchase Plan

The fair value for rights to purchase shares of common stock under the Company’s employee stock purchase plan was estimated on the date of grant using the following assumptions:

 

     Nine months ended
September 30,
    Three months ended
September 30,
 
     2017     2016     2017     2016  
     (unaudited)     (unaudited)     (unaudited)     (unaudited)  

Expected dividend yield

     0     0     0     0

Expected volatility

     28%-46     29%-57     28%-43     29%-48

Risk-free interest rate

     0.5%-1.1     0.3%-0.5     0.6%-1.1     0.4%-0.5

Expected forfeiture

     0     0     0     0

Contractual term of up to

     24 months       24 months       24 months       24 months